Literature DB >> 1856630

Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases.

P Basse1, R B Herberman, U Nannmark, B R Johansson, M Hokland, K Wasserman, R H Goldfarb.   

Abstract

While close contact between lymphokine-activated killer (LAK)/adherent, lymphokine-activated killer (A-LAK) cells and tumor cells is believed to be a prerequisite for initiating the events leading to tumor cell lysis, clear evidence for the ability of these effector cells to infiltrate tumors or tumor metastases in vivo still has to be obtained. In the present study, we report that a significant fraction of adoptively transferred A-LAK cells, labeled with fluorochromes for identification, accumulates in lung and liver metastases of the B16 melanoma, the MCA 102 sarcoma and the Lewis lung carcinoma lines. Thus, 5- to 10-fold higher numbers of A-LAK cells were found in the malignant lesions compared to the surrounding normal tissue. The infiltration seemed very heterogeneous after intravenous injection of moderate numbers of A-LAK cells (15 x 10(6)). However, after adoptive transfer of 45 million A-LAK cells, an A-LAK cell/tumor cell ratio higher than 1:1 in most metastases was observed. Surprisingly, approximately 5% of the lung metastases seemed totally resistant to infiltration even though neighboring metastases were highly infiltrated. While substantial infiltration of lung metastases was seen after i.v. injection, significant infiltration of liver metastases was seen only after intraportal injection of the A-LAK cells indicating impaired traffic of intravenous injected A-LAK cells through the lung capillaries. These results present direct evidence that A-LAK cells, upon a proper route of administration, have the potential to migrate to and heavily infiltrate metastases from murine tumors of different origin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1856630      PMCID: PMC2118902          DOI: 10.1084/jem.174.2.479

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  Fate of tumor cells injected into left ventricle of heart in BALB/c mice: role of natural killer cells.

Authors:  P Basse; P Hokland; I Heron; M Hokland
Journal:  J Natl Cancer Inst       Date:  1988-07-06       Impact factor: 13.506

Review 2.  Cell-mediated cytotoxic reactions.

Authors:  R H Goldfarb
Journal:  Hum Pathol       Date:  1986-02       Impact factor: 3.466

3.  Direct fluorescent labeling of cells with fluorescein or rhodamine isothiocyanate. II. Potential application to studies of lymphocyte migration and maturation.

Authors:  E C Butcher; R G Scollay; I L Weissman
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

4.  In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats.

Authors:  R E Felgar; J C Hiserodt
Journal:  Cell Immunol       Date:  1990-09       Impact factor: 4.868

5.  Lymphocytes stimulated with recombinant human interleukin-2: relationship between motility into protein matrix and in vivo localization in normal and neoplastic tissues of mice.

Authors:  S Ratner
Journal:  J Natl Cancer Inst       Date:  1990-04-04       Impact factor: 13.506

Review 6.  Mechanisms of lymphocyte traffic in neoplasia.

Authors:  S Ratner; G H Heppner
Journal:  Anticancer Res       Date:  1986 May-Jun       Impact factor: 2.480

7.  Gangliosides as receptors for fibronectin? Comparison of cell spreading on a ganglioside-specific ligand with that on fibronectin.

Authors:  R M Perkins; S Kellie; B Patel; D R Critchley
Journal:  Exp Cell Res       Date:  1982-10       Impact factor: 3.905

8.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

Authors:  M Rosenstein; I Yron; Y Kaufmann; S A Rosenberg
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

9.  Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.

Authors:  R Lafreniere; S A Rosenberg
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

10.  Assessment of in vivo natural antitumor resistance and lymphocyte. Migration in mice: comparison of 125I-iododeoxyuridine with 111indium-oxine and 51chromium as cell labels.

Authors:  R H Wiltrout; E Gorelik; M J Brunda; H T Holden; R B Herberman
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

View more
  26 in total

1.  Innocuousness and intracellular distribution of PKH67: a fluorescent probe for cell proliferation assessment.

Authors:  C Rousselle; M Barbier; V V Comte; C Alcouffe; J Clement-Lacroix; G Chancel; X Ronot
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001 Nov-Dec       Impact factor: 2.416

2.  Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis.

Authors:  M Watanabe; K L McCormick; K Volker; J R Ortaldo; J M Wigginton; M J Brunda; R H Wiltrout; W E Fogler
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Confusion about the tissue distribution of lymphokine-activated killer (LAK) cells.

Authors:  A A Maghazachi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Generation of cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate by CD38 for Ca2+ signaling in interleukin-8-treated lymphokine-activated killer cells.

Authors:  So-Young Rah; Mazhar Mushtaq; Tae-Sik Nam; Suhn Hee Kim; Uh-Hyun Kim
Journal:  J Biol Chem       Date:  2010-05-04       Impact factor: 5.157

5.  The microscopic anatomy of experimental rat CC531 colon tumour metastases: consequences for immunotherapy?

Authors:  M Hagenaars; N G Ensink; P H Basse; M Hokland; U Nannmark; A M Eggermont; C J van de Velde; G J Fleuren; P J Kuppen
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 6.  The immunobiological effects of interleukin-2 in vivo.

Authors:  R A Janssen; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

Review 7.  Immunotherapy in Sarcoma: Future Horizons.

Authors:  Melissa Burgess; Vikram Gorantla; Kurt Weiss; Hussein Tawbi
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

8.  Trafficking, persistence, and activation state of adoptively transferred allogeneic and autologous Simian Immunodeficiency Virus-specific CD8(+) T cell clones during acute and chronic infection of rhesus macaques.

Authors:  Diane L Bolton; Jacob T Minang; Matthew T Trivett; Kaimei Song; Jennifer J Tuscher; Yuan Li; Michael Piatak; David O'Connor; Jeffrey D Lifson; Mario Roederer; Claes Ohlen
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

9.  Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes.

Authors:  D J Cole; J K Taubenberger; B A Pockaj; J R Yannelli; C Carter; J Carrasquillo; S Leitman; S M Steinberg; S A Rosenberg; Y C Yang
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

10.  T-bet plays a key role in NK-mediated control of melanoma metastatic disease.

Authors:  Miriam B F Werneck; Geanncarlo Lugo-Villarino; Eun Sook Hwang; Harvey Cantor; Laurie H Glimcher
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.